Does hypertension history in patients with advanced gastric cancer has an impact on clinical outcomes following apatinib treatment? A subgroup analysis based on data from Ahead-G201 study

Authors :: Jianwei Yang
Jin Li
Yi Ba
Tongfu Jia
Zhong Xie
Mei Wang
Xiang-Yuan Wu
Yuxian Bai
Feng Ye
Guifang Zhang
Yong Huang
Haijun Zhong
Wenying Deng
Likun Liu
Lu Wen
Xiaoyan Lin
Shukui Qin
Tienan Yi
Junsheng Wang
Yifu He
Source :: Journal of Clinical Oncology. 36:e16022-e16022
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e16022Background: Hypertension (HTN) is one of the most common adverse events (AEs) associated with apatinib treatment in gastric carcinoma. However, few studies focus on the effect of HTN history ...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Subgroup analysis
Gastric carcinoma
Advanced gastric cancer
chemistry.chemical_compound
chemistry
Internal medicine
Medicine
Apatinib
In patient
cardiovascular diseases
business
Adverse effect

Full Text Access

Tools